This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
ICOTYDE™ (icotrokinra)
Medical Information
ICOTYDE - Use in Combination with Oral Medications in Patients with Plaque Psoriasis
Last Updated: 03/18/2026
SUMMARY
- The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
- ICOTYDE in combination with other oral medications has not been studied in patients with plaque psoriasis.
- Exclusion criteria related to concomitant therapy in the ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1, and ICONIC-ADVANCE-2 phase 3 trials is listed below.1
- 3
CLINICAL TRIAL PROTOCOLS
Exclusion Criteria
Prior or Concomitant Therapy
- Previously received ICOTYDE.1-3
- Prohibited medications or class of medications are provided in Table: Select Prohibited Medications in Phase 3 Clinical Trials.1-3
| Prohibited Medication or Class of Medications | Restriction Duration |
|---|---|
| Systemic immunomodulating treatments, including but not limited to: | 4 weeks prior to the first administration of study intervention (through end of study) |
| Methotrexate, azathioprine, cyclosporine A, corticosteroids, cyclophosphamide, tofacitinib, apremilast, deucravacitinib | |
| Systemic medications that could affect psoriasis evaluations, including but not limited to: | |
| Acitretin, retinoids, herbal treatments, or traditional Taiwanese, Korean, or Chinese medicines | |
| Nonbiologic experimental therapies or investigational agents |
Literature Search
A literature search of MEDLINE®
References
| 1 | Bissonnette R, Soung J, Hebert AA, et al. Protocol to: Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393(18):1784-1795. |
| 2 | |
| 3 |